Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Psoriasis from the inside out: how treatment works

A simple explanation of a psoriasis plaque and why skin and joint treatments must be chosen in their own clinical context.

In this article

A plaque is the visible end of an immune process

A psoriasis plaque is more than dry skin. It is the visible result of a continuing conversation between immune cells and the cells that form the skin. That conversation accelerates skin-cell production, disrupts normal maturation and keeps inflammation active. Understanding the sequence makes treatment names less mysterious: different medicines interrupt different parts of the same process.

Psoriasis is not contagious. It is not evidence of poor hygiene, and vigorous washing or scraping does not remove its cause. The effects can extend well beyond appearance: itching, cracks, bleeding, pain, disturbed sleep and embarrassment may interfere with work, relationships and ordinary activities. A small affected area can be a major problem when it involves the hands, soles, genitals, face or scalp.

What happens inside the plaque

Classic plaques have a defined edge and an overlying scale. Their color varies with skin tone; inflammation may look pink or red, violet, or darker than surrounding skin. A dermatologist also considers location, nail changes and conditions that can resemble psoriasis. Appearance alone is not always enough for a diagnosis.

Under a microscope, the outer skin layer—the epidermis—is thickened. This is called acanthosis. Its lower border forms elongated downward projections, the rete ridges. Skin cells move toward the surface before completing normal maturation; some retain their nuclei within the scale, a change called parakeratosis. Certain white blood cells, neutrophils, can collect in tiny clusters called Munro microabscesses. These microscopic clusters do not, by themselves, mean a bacterial infection.

Small blood vessels beneath the surface become enlarged and lie close to the scale. Removing scale can therefore cause pinpoint bleeding, historically called the Auspitz sign. It is a clinical observation, not a test to try at home. Scratching and injury can worsen lesions, and psoriasis may appear at injured sites—the Koebner phenomenon.

The immune loop: IL-23, IL-17 and skin cells

Keratinocytes are the main cells of the epidermis. In susceptible people, stressed or injured keratinocytes release signals that activate immune cells. One proposed initiating route involves the antimicrobial peptide LL-37 interacting with the body's own nucleic acids and stimulating dendritic cells. This is a useful biological model, not a single proven trigger for every person's psoriasis.

Dendritic cells help activate T cells. The messenger protein IL-23 sustains an inflammatory response involving Th17 cells. IL-17, together with other signals including TNF and IL-22, stimulates keratinocytes. The skin cells then produce additional inflammatory signals and recruit more immune cells. The loop can keep running after the original trigger has gone.

This explains why a plaque can recur in the same place and why simply removing scale does not reliably prevent its return. It also explains why targeted treatment can work: interrupting an important messenger can quiet the conversation. Psoriasis biology is more complex than one straight line; a drug's position in a diagram does not tell us which drug is best for a particular person.

Part of the processWhat happensTreatment idea
Skin surfaceDryness, thickening, scaling and cracksMoisturizers and appropriate topical treatment
Immune signals outside cellsTNF, IL-17 or IL-23 help sustain inflammationBiologics block selected signals
Signaling inside cellsCells translate incoming messages into an inflammatory responseSelected oral medicines alter intracellular pathways
Joint and tendon involvementInflammation may affect joints, tendon insertions or the spineChoose treatment for the actual pattern of psoriatic arthritis

Watch: how a psoriasis plaque forms

The original animation connects the visible plaque with changes in the skin and immune signals. Watch how the process moves from cells and signaling to the sites where different medicines act.

Original English video · Professional education. Olga Goodman, MD · RheumaView.

Open video separately · Original article

What to look for. Keratinocytes are the main cells of the epidermis. IL-23 and IL-17 are immune signals discussed in the article. The film’s broader medicine overview should be read alongside the distinction between skin and joint treatment below.

Not every rheumatology medicine shown is an established treatment for plaque psoriasis. Indications differ by drug, disease manifestation and country; a mechanism diagram does not rank treatments.

Topical treatment and phototherapy still have a role

Moisturizers support the skin barrier and reduce discomfort, but do not replace treatment when inflammation needs control. Prescription creams, ointments, foams and solutions may contain corticosteroids, vitamin-D analogues or other anti-inflammatory medicines. The body site matters: a product suited to thick plaques on the elbows may be inappropriate for eyelids or genital skin. Strength, duration and the amount used should be part of the prescription discussion.

Medical phototherapy uses a controlled ultraviolet-light schedule with attention to skin type, exposure and adverse effects. A tanning bed is not an equivalent treatment. Practical issues—travel, appointment frequency and the areas involved—also influence whether phototherapy is a realistic choice.

Where systemic medicines act

Conventional medicines act more broadly. Methotrexate affects several inflammatory and metabolic pathways; its anti-inflammatory action cannot be reduced to “killing fast-growing skin.” It may be used for psoriasis and selected patterns of psoriatic arthritis. Other conventional treatments have different purposes and monitoring requirements. Medicines used in rheumatology are not automatically treatments for psoriasis: hydroxychloroquine is not routine plaque-psoriasis therapy and can aggravate psoriasis in some people. Leflunomide or sulfasalazine may have a role in selected joint disease without being interchangeable with skin-directed treatment.

Biologics are antibodies or related proteins that act on selected targets outside cells. Important psoriasis targets include TNF, IL-17 and IL-23; some agents target the shared IL-12/23 pathway. Blocking one of these signals can reduce plaque inflammation. Different drugs have different indications and effects across skin, peripheral joints and axial disease. A long list of biologics is not a list of equally suitable choices.

Targeted oral medicines act inside cells. Apremilast inhibits PDE4 and changes intracellular signaling through cyclic AMP. Deucravacitinib targets TYK2, a signaling protein involved in pathways including IL-23. Other JAK-directed medicines have roles in selected inflammatory joint diseases. These families differ in selectivity, evidence, indications, warnings and monitoring; “oral” does not mean mild, and “targeted” does not mean risk-free.

The treatment landscape changes. The current prescribing information for the exact medicine and country should determine its indication. A mechanism animation does not establish approval, comparative effectiveness or suitability during pregnancy.

When the joints change the decision

Psoriatic arthritis can develop in a person with mild skin disease, and sometimes joint disease precedes recognized psoriasis. Tell your clinician about persistently swollen joints, a whole swollen finger or toe, heel or tendon-insertion pain, or back stiffness that behaves differently from ordinary muscular soreness. Nail pitting or separation can provide context but does not establish arthritis by itself.

Skin and joints share biology but are not identical treatment targets. A topical cream cannot protect an inflamed joint. Conversely, improvement in joint pain does not guarantee that scalp or genital psoriasis is adequately controlled. Eye inflammation, inflammatory bowel disease and other conditions can also change which medicine is preferable. Coordination between dermatology and rheumatology is particularly valuable when several areas are involved.

Choosing, monitoring and judging benefit

A treatment decision includes disease burden, affected sites, previous response, infections, liver or kidney disease, other medicines, pregnancy plans and personal preferences. Before some systemic treatments, clinicians assess tuberculosis and hepatitis risk, vaccination status and baseline laboratory results. Not every medicine requires the same screening or follow-up.

Agree on what improvement will look like: fewer plaques, less itch, restored sleep, better hand function or less joint swelling. Photographs taken in similar lighting can help follow skin changes. Record adverse effects and missed doses. Treatment response is usually assessed over an agreed interval rather than after one dose, but serious adverse effects require earlier contact.

Ask: Which problem is this medicine intended to treat? What should improve first? When will we reassess? Which monitoring is needed? What should I do during an infection or before surgery? Do not stop, combine or switch prescribed therapy using this article alone.

When to seek prompt help

Widespread redness, extensive pustules, fever or feeling acutely unwell needs urgent medical assessment. A painful red eye, light sensitivity or reduced vision warrants urgent eye assessment. A suddenly hot, very painful swollen joint may be infected even in someone with established psoriasis or arthritis. These situations should not wait for a routine skin follow-up.

The practical goal is broader than clearing scale: understand which tissues are affected, choose a treatment that reaches those tissues and check whether it delivers the benefit that matters to you.

Sources and further reading

Expanded patient edition based on the original publications, with additional explanations and clinical context. The source articles retain their original professional or narrative format.

Original RheumaView articles by Olga Goodman, MD

Clinical references

© Olga Goodman, MD · Reuse requires attribution and a link to the original publication.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: How treatment works